Conventional Therapies TM Immune Therapies
Mucosal immune response Oral vaccines have not been developed. They enhance Peyer’s batches activation and increase the production of IgA+B cells and SIgA.
Innate immune response
(a) The development and research of vaccines are mainly based on inhibiting the bacterial immune evasion from innate immune responses, for example, targeting virulence factors by blocking the complement system and killing neutrophils. (b) AAC therapy facilitates bacterial uptake by phagocytic cells through opsonizing by antibodies. (a) Targeting the complement system: They influence the complement system to regulate the development of MRSA infection. (b) Targeting neutrophil phagocytosis: They act on neutrophil migration and recruitment, chemokine expression, macrophage activity and antigen presentation.
Adaptive immune response
The development and research of passive immunotherapy also targets the molecules or components mediated immune evasion.
(a) Targeting T-cell activation: They stimulate T-cell activation and enhancing T-lymphocyte proliferation. (b) Targeting antibodies: They increase B-cell activation and antibody titers. (c) Targeting MRSA immune evasion strategies: They inhibit the formation of bacterial BFs.